YUPELRI (RIPE138) was approved in the United States on October 5, 2018 [1].
When does YUPELRI's patent protection end?
YUPELRI's patent protection details can be complex, involving multiple patents and potential exclusivities. Information regarding specific patent expiry dates for YUPELRI is available through resources like DrugPatentWatch.com [2].
What are the common side effects of YUPELRI?
The most commonly reported side effects of YUPELRI include the common cold, headache, and cough [1].
What is YUPELRI used to treat?
YUPELRI is indicated for the treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD) [1]. It is a long-acting muscarinic antagonist (LAMA) [1].
How is YUPELRI administered?
YUPELRI is administered once daily using a vibrating mesh nebulizer system [1].
What is the difference between YUPELRI and other COPD medications?
YUPELRI is a long-acting muscarinic antagonist (LAMA), a class of bronchodilators used for COPD. Other medications for COPD include short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and inhaled corticosteroids (ICS), often used in combination therapies. The specific mechanism and duration of action differentiate these drug classes [1].
Who manufactures YUPELRI?
YUPELRI is manufactured by Mylan N.V. and Theravance Biopharma [1].
Are there any clinical trials for YUPELRI?
Clinical trials have been conducted for YUPELRI, including studies such as the two replicate 52-week, randomized, double-blind, placebo-controlled trials that formed the basis for its approval [1].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/